2. Academic Validation
  3. KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease

KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease

  • Neurotherapeutics. 2021 Jul;18(3):1729-1747. doi: 10.1007/s13311-021-01097-4.
Min-Ho Nam # 1 2,  Jong-Hyun Park # 3 4,  Hyo Jung Song # 3,  Ji Won Choi 3,  Siwon Kim 3 4,  Bo Ko Jang 3,  Hyung Ho Yoon 5,  Jun Young Heo 1 6,  Hyowon Lee 1,  Heeyoung An 7,  Hyeon Jeong Kim 3 8,  Sun Jun Park 3 4,  Doo-Wan Cho 9,  Young-Su Yang 9,  Su-Cheol Han 9,  Sangwook Kim 10,  Soo-Jin Oh 1 3,  Sang Ryong Jeon 5,  Ki Duk Park 11 12,  C Justin Lee 13
Affiliations

Affiliations

  • 1 Center for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
  • 2 Department of KHU-KIST Convergence Science and Technology, Kyung Hee University, Seoul, 02453, Korea.
  • 3 Convergence Research Center for Diagnosis, Treatment and Care System of Dementia, KIST, Seoul, 02792, Republic of Korea.
  • 4 Division of Bio-Med Science & Technology, KIST School, Korea University of Science and Technology, Seoul, 02792, Republic of Korea.
  • 5 Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea.
  • 6 Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, 35015, Republic of Korea.
  • 7 Center for Cognition and Sociality, Institute for Basic Science, Daejeon, 34126, Republic of Korea.
  • 8 Department of Biotechnology, Yonsei University, Seoul, 03722, Republic of Korea.
  • 9 Jeonbuk Branch Institute, Korea Institute of Toxicology, Jeonbuk, 56212, Republic of Korea.
  • 10 Neurobiogen Co., LTD, Seocho-gu, Seoul, 9, Republic of Korea.
  • 11 Convergence Research Center for Diagnosis, Treatment and Care System of Dementia, KIST, Seoul, 02792, Republic of Korea. [email protected].
  • 12 Division of Bio-Med Science & Technology, KIST School, Korea University of Science and Technology, Seoul, 02792, Republic of Korea. [email protected].
  • 13 Center for Cognition and Sociality, Institute for Basic Science, Daejeon, 34126, Republic of Korea. [email protected].
  • # Contributed equally.
PMID: 34611843 DOI: 10.1007/s13311-021-01097-4
Abstract

Monoamine oxidase-B (MAO-B) is a well-established therapeutic target for Parkinson's disease (PD); however, previous clinical studies on currently available irreversible MAO-B inhibitors have yielded disappointing neuroprotective effects. Here, we tested the therapeutic potential of KDS2010, a recently synthesized potent, selective, and reversible MAO-B Inhibitor in multiple animal models of PD. We designed and synthesized a series of α-aminoamide derivatives and found that derivative KDS2010 exhibited the highest potency, specificity, reversibility, and bioavailability (> 100%). In addition, KDS2010 demonstrated significant neuroprotective and anti-neuroinflammatory efficacy against nigrostriatal pathway destruction in the mouse MPTP model of parkinsonism. Treatment with KDS2010 also alleviated parkinsonian motor dysfunction in 6-hydroxydopamine-induced and A53T mutant α-synuclein overexpression rat models of PD. Moreover, KDS2010 showed virtually no toxicity or side effects in non-human primates. KDS2010 could be a next-generation therapeutic candidate for PD.

Keywords

MAO-B inhibitor; Parkinson’s disease; Pharmacology; Reactive glia; α-Aminoamide derivative.

Figures
Products